The Nasus Pharma Ltd. (NSRX) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on the NYSE American. Nasus Pharma files reports with the U.S. Securities and Exchange Commission that include current information on its clinical programs, financial condition, governance, and material agreements.
Nasus Pharma submits current reports on Form 6-K, which have covered topics such as condensed unaudited interim financial statements and management’s discussion and analysis for specified periods, leadership appointments, clinical trial milestones, and collaboration agreements. For example, Form 6-K reports have described the appointment of an Executive Vice President and Chief Financial Officer, the initiation of a Phase 2 clinical study of NS002 with first participant dosed, and expanded agreements with Aptar France S.A.S. and AptarGroup, Inc. to support the intranasal epinephrine program.
Filings also document capital markets events, including the registration and completion of Nasus Pharma’s initial public offering on Form F-1 and subsequent updates on the partial exercise of the underwriters’ over-allotment option. These disclosures outline the company’s stated use of proceeds, such as funding further development of its intranasal epinephrine program and general corporate purposes, and provide detail on underwriting arrangements.
As a foreign private issuer, Nasus Pharma is required to file an annual report on Form 20-F, and it supplements this with periodic Form 6-K submissions when it releases press statements or corporate presentations that are material to investors. Some 6-K filings incorporate press releases, such as the CEO’s letter to shareholders or news of regulatory clearances, directly as exhibits.
On this page, users can review Nasus Pharma’s SEC filings as they are made available through the EDGAR system. Stock Titan enhances access by pairing filings with AI-powered summaries that help explain key sections, highlight clinical and financial themes, and make lengthy documents such as financial statements and management analyses easier to understand. Investors can quickly identify filings related to clinical progress of NS002, leadership and governance changes, capital raising activities, and significant collaboration agreements.
Nasus Pharma Ltd. reported that shareholders at its October 8, 2026 Annual and Special General Meeting approved all agenda items except Proposal No. 4, by the applicable required majority. A quorum was present. The report is incorporated by reference into the company’s Form F-3 and Form S-8 registration statements, subject to later-filed or furnished documents or reports.
Nasus Pharma Ltd (NSRX) Interim CFO Elmaliah Oren reported two direct share-option positions. As of September 18, 2026, 24,680 options were outstanding, fully vested and exercisable at $1.2264 per share, expiring November 28, 2029. A January 17, 2025 grant covered 27,460 options, of which 13,840 were vested and exercisable as of September 18, 2026, at $6.0462 per share, expiring January 17, 2035.
Nasus Pharma Ltd (NSRX) filed an Exit Form 4 reporting that Rubin Eyal, who served as Chief Financial Officer and Executive Vice President, ceased to serve in these roles effective September 18, 2026. As a result, he is no longer subject to Section 16 reporting obligations with respect to the company. The filing reports no share transactions.
Nasus Pharma Ltd (NSRX) is launching a primary at-the-market offering of up to $8,500,000 of ordinary shares under its Form F-3 shelf, using BTIG, LLC as sales agent. Sales, if any, will be made from time to time into the market at prevailing prices, and Nasus is not obligated to sell any shares.
BTIG will use commercially reasonable efforts to place shares and will receive up to 3% of gross proceeds as commission, with each sale treated as an underwritten transaction. Based on an illustrative price of $3.65 per share, selling 2,328,767 shares would increase shares outstanding from 11,710,808 to up to 14,042,575, creating an immediate dilution of $2.29 per share for new investors and a $0.42 per-share accretion in net tangible book value for existing holders.
Nasus plans to use net proceeds primarily for ongoing clinical development of its lead intranasal epinephrine candidate NS002 for anaphylaxis, to start clinical studies for additional pipeline products such as NS003, NS004 and NS005, and for working capital and general corporate purposes. The company highlights significant risks, including recurring losses, substantial additional capital needs, potential going concern issues, limited trading liquidity, and the possibility of further dilution from future equity financings or option and warrant exercises.
Nasus Pharma Ltd. (NSRX) entered into an At-The-Market Sales Agreement with BTIG, LLC, allowing the company to offer and sell ordinary shares from time to time through BTIG as sales agent under its effective Form F-3 shelf registration. Nasus is not obligated to sell any shares, and BTIG will use commercially reasonable efforts to execute sales as instructed by the company, in transactions deemed an “at the market offering” under Rule 415(a)(4). Nasus will pay BTIG a commission of up to 3.0% of aggregate gross proceeds and will provide customary indemnification and expense reimbursement. The company intends to use any net proceeds for ongoing clinical development of NS002 for anaphylaxis, initiation of clinical studies for other pipeline products, and for working capital and general corporate purposes.
Nasus Pharma Ltd. (NSRX) reports that the U.S. FDA has cleared its Investigational New Drug application for NS002, an intranasal epinephrine powder being developed for treatment of anaphylaxis. This clearance allows initiation of a new clinical study under the IND.
The company plans to begin a pivotal NS002 study in the fourth quarter of 2026 and anticipates a topline data readout in the first quarter of 2027. Nasus cites prior Phase 2 results in which NS002 achieved a 100 pg/mL plasma epinephrine threshold with a median time of 1.69 minutes, compared with 3.47 minutes for EpiPen, as it advances development in what it describes as a growing $2 billion anaphylaxis treatment market.
Nasus Pharma Ltd. (NSRX) has called an annual and special shareholder meeting for October 8, 2026 in Tel Aviv. Shareholders of record on September 14, 2026 will vote on auditor re-appointment, director re-elections, executive compensation items, and an increase in shares reserved under the U.S. stock option sub-plan.
Key proposals include approving a new compensation package for CEO Brendan P. O’Grady, featuring a $500,000 base salary, performance bonus eligibility and 280,000 stock options with tiered exercise prices, and a one-time $70,000 bonus to former CEO Dan Teleman tied to a $15.0 million PIPE financing completed in February 2026.
Shareholders are also asked to increase the pool of ordinary shares qualifying as incentive stock options for U.S. persons from 105,611 to 305,611 shares. Proposals on auditor, directors, and plan share increase require a Simple Majority, while the CEO and former CEO compensation items require a Special Majority under Israeli Companies Law.
Nasus Pharma Ltd. (NSRX) filed a Form F-3 shelf registration to offer and sell from time to time up to $50,000,000 of its ordinary shares, no par value. Specific pricing, amounts and distribution terms for each takedown will be detailed in future prospectus supplements.
Nasus is a clinical-stage specialty pharmaceutical company developing powder-based intranasal (PBI) products, led by NS002 intranasal epinephrine and NS003 intranasal ondansetron, with additional preclinical programs NS004 and NS005. The company has no FDA‑approved products, has incurred significant losses, and reported an accumulated deficit of about $24.5 million as of June 30, 2026.
Ordinary shares trade on NYSE American under the symbol NSRX; on August 31, 2026, the last reported sale price was $4.084 per share, and non‑affiliate market value was approximately $22.7 million based on 11,713,808 shares outstanding. As of June 30, 2026, cash, cash equivalents, restricted cash and a short‑term deposit totaled $11.9 million and shareholders’ equity was $11.0 millionemerging growth company and a foreign private issuer, which allows reduced reporting and governance requirements compared with U.S. domestic issuers.